Month: November 2022

On November 7, 1997, Plummer, Mark S.; Holland, Debra R.; Shahripour, Aurash; Lunney, Elizabeth A.; Fergus, James H.; Marks, James S.; McConnell, Patrick; Mueller, W. Thomas; Sawyer, Tomi K. published an article.Formula: C10H19NO4 The title of the article was Design, Synthesis, and Cocrystal Structure of a Nonpeptide Src SH2 Domain Ligand. And the article contained the following:

The specific association of an SH2 domain with a phosphotyrosine (pTyr)-containing sequence of another protein precipitates a cascade of intracellular mol. interactions (signals) which effect a wide range of intracellular processes. The nonreceptor tyrosine kinase Src, which has been associated with breast cancer and osteoporosis, contains an SH2 domain. Inhibition of Src SH2-phosphoprotein interactions by small mols. will aid biol. proof-of-concept studies which may lead to the development of novel therapeutic agents. Structure-based design efforts have focused on reducing the size and charge of Src SH2 ligands while increasing their ability to penetrate cells and reach the intracellular Src SH2 domain target. In this report we describe the synthesis, binding affinity, and Src SH2 cocrystal structure of a small, novel, nonpeptide, urea-containing SH2 domain ligand. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Formula: C10H19NO4

The Article related to src sh2 domain nonpeptide ligand preparation, Pharmacology: Structure-Activity and other aspects.Formula: C10H19NO4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On January 25, 2018, Crew, Andrew P.; Raina, Kanak; Dong, Hanqing; Qian, Yimin; Wang, Jing; Vigil, Dominico; Serebrenik, Yevgeniy V.; Hamman, Brian D.; Morgan, Alicia; Ferraro, Caterina; Siu, Kam; Neklesa, Taavi K.; Winkler, James D.; Coleman, Kevin G.; Crews, Craig M. published an article.SDS of cas: 882518-89-0 The title of the article was Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. And the article contained the following:

Proteolysis Targeting Chimeras (PROTACs) are bifunctional mols. that recruit an E3 ligase to a target protein to facilitate ubiquitination and subsequent degradation of that protein. While the field of targeted degraders is still relatively young, the potential for this modality to become a differentiated and therapeutic reality is strong, such that both academic and pharmaceutical institutions are now entering this interesting area of research. In this paper, the authors describe a broadly applicable process for identifying degrader hits based around the serine/threonine kinase TANK-binding kinase 1 (TBK1), and have generalized the key structural elements associated with degradation activities. Compound I is a potent hit (TBK1 DC50 = 12 nM, Dmax = 96%) with excellent selectivity against a related kinase IKKε, which was further used as a chem. tool to assess TBK1 as a target in mutant K-Ras cancer cells. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).SDS of cas: 882518-89-0

The Article related to von hippel lindau protac tank binding kinase 1, Pharmacology: Structure-Activity and other aspects.SDS of cas: 882518-89-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 26, 2010, Huang, Adrian; Moretto, Alessandro; Janz, Kristin; Lowe, Michael; Bedard, Patricia W.; Tam, Steve; Di, Li; Clerin, Valerie; Sushkova, Natalia; Tchernychev, Boris; Tsao, Desiree H. H.; Keith, James C. Jr.; Shaw, Gray D.; Schaub, Robert G.; Wang, Qin; Kaila, Neelu published an article.Application of 141940-37-6 The title of the article was Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury. And the article contained the following:

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclin. development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Application of 141940-37-6

The Article related to quinoline preparation p selectin inhibitor sar, Pharmacology: Structure-Activity and other aspects.Application of 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 10, 2013, Betschart, Claudia; Hintermann, Samuel; Behnke, Dirk; Cotesta, Simona; Fendt, Markus; Gee, Christine E.; Jacobson, Laura H.; Laue, Grit; Ofner, Silvio; Chaudhari, Vinod; Badiger, Sangamesh; Pandit, Chetan; Wagner, Juergen; Hoyer, Daniel published an article.SDS of cas: 1198284-94-4 The title of the article was Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia. And the article contained the following:

Dual orexin receptor (OXR) antagonists (DORAs) such as almorexant, 1 (SB-649868), or suvorexant have shown promise for the treatment of insomnias and sleep disorders in several recent clin. trials in volunteers and primary insomnia patients. The relative contribution of antagonism of OX1R and OX2R for sleep induction is still a matter of debate. We therefore initiated a drug discovery project with the aim of creating both OX2R selective antagonists and DORAs. Here we report that the OX2R selective antagonist 26 induced sleep in mice primarily by increasing NREM sleep, whereas the DORA suvorexant induced sleep largely by increasing REM sleep. Thus, OX2R selective antagonists may also be beneficial for the treatment of insomnia. The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).SDS of cas: 1198284-94-4

The Article related to preparation orexin receptor antagonist sleep insomnia, Pharmacology: Structure-Activity and other aspects.SDS of cas: 1198284-94-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 19, 2020, Roberts, Brett L.; Ma, Zhi-Xiong; Gao, Ang; Leisten, Eric D.; Yin, Dan; Xu, Wei; Tang, Weiping published an article.Application In Synthesis of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate The title of the article was Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders. And the article contained the following:

Proteolysis targeting chimeras (PROTACs) have emerged as useful chem. probes and potential therapeutics by taking advantage of the ubiquitin-proteasome system to degrade intracellular disease-associated proteins. PROTACs are heterobifunctional mols. composed of a target protein ligand, E3 ubiquitin ligase ligand, and a linker between them. The generation of efficient PROTACs requires screening of many parameters, especially the lengths and types of the linkers. The authors report the proof-of-concept study using a two-stage strategy to facilitate the development of PROTACs against the estrogen receptor (ER). In stage one, a library of close to 100 PROTACs was synthesized by simply mixing a library of ERα ligands containing a hydrazide functional group at different positions with a preassembled library of E3 ligase ligands bearing different types and lengths of linkers with a terminal aldehyde group in a 1:1 ratio. Cell-based screening occurred without further purification, because the formation of the acylhydrazone linkage is highly efficient and produces water as the only byproduct. Compound A3 was the most potent ER degrader in two ER+ cell lines (DC50= ~10 nM, Dmax= â‰?95%). Stage two involved transformation to a more stable amide linker to generate a more drug-like mol. The new compound, AM-A3, showed comparable biol. activity (DC50 = 1.1 nM, Dmax = 98%) and induced potent antiproliferation (IC50= 13.2 nM, Imax= 69%) in MCF-7. This proof-of -concept study demonstrates that the two-stage strategy can significantly facilitate the development of PROTACs against ER without the tedious process of making large numbers of PROTACs one by one. It has the potential to be expanded to many other targets. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Application In Synthesis of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate

The Article related to proteolysis targeting chimera estrogen receptor degrader, Pharmacology: Structure-Activity and other aspects.Application In Synthesis of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On May 15, 2010, Zhang, Xiaotong; Bao, Ye; Huang, Ke; Barnett-Rundlett, Kimber L.; Armstrong, Daniel W. published an article.Computed Properties of 6038-19-3 The title of the article was Evaluation of dalbavancin as chiral selector for HPLC and comparison with teicoplanin-based chiral stationary phases. And the article contained the following:

Dalbavancin is a new compound of the macrocyclic glycopeptide family. It was covalently linked to 5 μm silica particles using two different binding chemistries. Approx. 250 racemates including (a) heterocyclic compounds, (b) chiral acids, (c) chiral amines, (d) chiral alcs., (e) chiral sulfoxides and sulfilimines, (f) amino acids and amino acid derivatives, and (g) other chiral compounds were tested on the two new chiral stationary phases (CSPs) using three different mobile phases. As dalbavancin is structurally related to teicoplanin, the same set of chiral compounds was screened on two com. available teicoplanin CSPs for comparison. The dalbavancin CSPs were able to sep. some enantiomers that were not separated by the teicoplanin CSPs and also showed improved separations for many racemates. However, there were other compounds only separated or better separated on teicoplanin CSPs. Therefore, the dalbavancin CSPs are complementary to the teicoplanin CSPs. Chirality, 2010. © 2009 Wiley-Liss, Inc. The experimental process involved the reaction of 3-Aminodihydrothiophen-2(3H)-one hydrochloride(cas: 6038-19-3).Computed Properties of 6038-19-3

The Article related to dalbavancin chiral selector hplc teicoplanin stationary phase, Pharmaceutical Analysis: General and other aspects.Computed Properties of 6038-19-3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 18, 1996, Klein, Scott; Molino, Bruce F.; Czekaj, Mark; Dener, Jeffrey S.; Leadley, Robert J.; Sabatino, Ralph; Dunwiddie, Christopher T.; Chu, Valeria published an article.HPLC of Formula: 53838-27-0 The title of the article was Non-peptide fibrinogen receptor antagonists based upon a 4-substituted piperidine scaffold. And the article contained the following:

Structure-activity relationships developed from work with peptide based fibrinogen receptor antagonists have been successfully applied to the development of simple and highly potent nonpeptide agents of the same class. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).HPLC of Formula: 53838-27-0

The Article related to fibrinogen receptor antagonist trimethylene dipiperidine derivative, Pharmacology: Structure-Activity and other aspects.HPLC of Formula: 53838-27-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 11, 2010, Jarvis, Ashley; Allerston, Charles K.; Jia, Haiyan; Herzog, Birger; Garza-Garcia, Acely; Winfield, Natalie; Ellard, Katie; Aqil, Rehan; Lynch, Rosemary; Chapman, Chris; Hartzoulakis, Basil; Nally, James; Stewart, Mark; Cheng, Lili; Menon, Malini; Tickner, Michelle; Djordjevic, Snezana; Driscoll, Paul C.; Zachary, Ian; Selwood, David L. published an article.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate The title of the article was Small Molecule Inhibitors of the Neuropilin-1 Vascular Endothelial Growth Factor A (VEGF-A) Interaction. And the article contained the following:

We report the mol. design and synthesis of EG00229, 2, the first small mol. ligand for the VEGF-A receptor neuropilin 1 (NRP1) and the structural characterization of NRP1-ligand complexes by NMR spectroscopy and X-ray crystallog. Mutagenesis studies localized VEGF-A binding in the NRP1 b1 domain and a peptide fragment of VEGF-A was shown to bind at the same site by NMR, providing the basis for small mol. design. Compound 2 demonstrated inhibition of VEGF-A binding to NRP1 and attenuated VEGFR2 phosphorylation in endothelial cells. Inhibition of migration of endothelial cells was also observed The viability of A549 lung carcinoma cells was reduced by 2, and it increased the potency of the cytotoxic agents paclitaxel and 5-fluorouracil when given in combination. These studies provide the basis for design of specific small mol. inhibitors of ligand binding to NRP1. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

The Article related to neuropilin vegf inhibitor design antitumor combination chemotherapy, Pharmacology: Structure-Activity and other aspects.Reference of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Saito, Sayuri; Yamakoshi, Hiroyuki; Nakamura, Seiichi published an article in 2019, the title of the article was Second-generation synthesis of a chiral building block for oxygenated terpenoids via a ring-contractive coupling with a secondary alcohol.Application In Synthesis of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate And the article contains the following content:

A much improved second-generation synthesis of a chiral building block, developed for the syntheses of C17-oxygenated steroids/triterpenoids e.g., cortisol and C9-oxygenated labdane diterpenoids (marrubiin and marrulibacetal), was accomplished by exploiting a ring-contractive coupling between an α-bromo-δ-valerolactone (3R)/(3S)-I and (R)-seudenol, wherein the use of t-BuOK as a base allowed clean conversion to the corresponding tetrahydrofuran-2-carboxylate (2S)/(2R)-II even with a small excess of the alc. component. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Application In Synthesis of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate

The Article related to terpenoid preparation, seudenol bromo valerolactone ring contraction coupling, Terpenes and Terpenoids: General and other aspects.Application In Synthesis of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 14, 2019, Wang, Shuai; Zhao, Lijie; Shi, Xiao-Jing; Ding, Lina; Yang, Linlin; Wang, Zhi-Zheng; Shen, Dandan; Tang, Kai; Li, Xiao-Jing; Mamun, MAA; Li, Huiju; Yu, Bin; Zheng, Yi-Chao; Wang, Shaomeng; Liu, Hong-Min published an article.Related Products of 10472-24-9 The title of the article was Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5-a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein Interaction. And the article contained the following:

The cullin-RING ubiquitin ligases (CRLs) are responsible for about 20% of cellular protein degradation and regulate diverse cellular processes, and the dysfunction of CRLs is implicated in human diseases. Targeting the CRLs has become an emerging strategy for the treatment of human diseases. Herein, we describe the discovery of a hit compound from our inhouse library and further structure-based optimizations, which have enabled the identification of new triazolo[1,5-a]pyrimidine-based inhibitors targeting the DCN1-UBC12 interaction. Compound WS-383 blocks the DCN1-UBC12 interaction (IC50 = 11 nM) reversibly and shows selectivity over selected kinases. WS-383 exhibits cellular target engagement to DCN1 in MGC-803 cells. WS-383 inhibits Cul3/1 neddylation selectively over other cullins and also induces accumulation of p21, p27, and NRF2. Collectively, targeting the DCN1-UBC12 interaction would be a viable strategy for selective neddylation inhibition of Cul3/1 and may be of therapeutic potential for disease treatment in which Cul3/1 is dysregulated. The experimental process involved the reaction of Methyl 2-cyclopentanonecarboxylate(cas: 10472-24-9).Related Products of 10472-24-9

The Article related to triazolo pyrimidine derivative preparation dcn1 ubc12 protein interaction cancer, Pharmacology: Structure-Activity and other aspects.Related Products of 10472-24-9

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics